jdm

Journal of Diabetes & Metabolism

ISSN - 2155-6156

Expert Review - (2023) Volume 14, Issue 6

View PDF Download PDF

Type 2 Diabetes Management Quality Indicators in Cancer Survivors: A Comparative Analysis

Maltie Harewood*
 
*Correspondence: Maltie Harewood, Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, Barbados, Email:

Author info »

Abstract

Cancer survivors with type 2 diabetes mellitus (T2DM) face unique challenges in managing their diabetes care due to the long-term effects of cancer treatment. This article presents a comparative analysis of type 2 diabetes management quality indicators in cancer survivors, aiming to assess the quality of diabetes care and identify areas for improvement in this specific patient population [1]. The study examines various quality indicators, including glycemic control, blood pressure management, lipid profile, preventive care, and adherence to diabetes medications and screenings. By analyzing these indicators, healthcare providers can enhance diabetes management strategies and improve long-term outcomes for cancer survivors with T2DM [2].

Keywords

Type 2 diabetes; Cancer survivors; Quality indicators; Comparative analysis; diabetes management; Healthcare delivery; Cancer treatments; Glycemic control

Introduction

Type 2 diabetes (T2D) and cancer are two prevalent and complex health conditions that often coexist, requiring specialized care for individuals who are cancer survivors with diabetes. Managing diabetes effectively is crucial for cancer survivors as it contributes to overall health, quality of life, and optimal treatment outcomes. Quality indicators serve as important measures to evaluate the adequacy of diabetes management in this specific population [3].

A comparative analysis of type 2 diabetes management quality indicators in cancer survivors aims to explore the existing standards of care, identify potential gaps in diabetes management, and propose strategies for optimizing healthcare delivery in this unique patient population [4, 5].

Cancer survivors, who have completed their cancer treatment, may face distinct challenges in managing their diabetes due to various factors such as the side effects of cancer therapies, altered metabolic processes, and the need for comprehensive and coordinated care. It is essential to evaluate the quality indicators that are relevant to this population and understand how they can be effectively implemented to improve diabetes management outcomes. This comparative analysis will assess the current state of type 2 diabetes management quality indicators in cancer survivors by examining relevant guidelines, clinical protocols, and research studies. By comparing and contrasting the indicators across different healthcare settings, we can gain insights into the variations in care and identify areas for improvement [6].

Furthermore, the analysis will explore the specific challenges faced by cancer survivors with type 2 diabetes, including the impact of cancer treatments on glycemic control, the need for interdisciplinary care coordination, and the role of patient education and empowerment in self-management [7].

By highlighting the gaps and variations in type 2 diabetes management quality indicators in cancer survivors, this analysis aims to provide recommendations for enhancing care delivery and optimizing outcomes. The findings can inform healthcare professionals, policymakers, and researchers on potential strategies to improve the integration of diabetes management into cancer survivorship care and promote holistic patient-centered approaches [8].

Glycemic control

Achieving and maintaining optimal glycemic control is essential in managing T2DM in cancer survivors. The comparative analysis examines indicators such as hemoglobin A1c (HbA1c) levels, blood glucose monitoring, and the use of diabetes medications to assess the effectiveness of glycemic control strategies. The analysis aims to identify potential barriers and areas for improvement in achieving target HbA1c levels in cancer survivors [9].

Blood pressure management

Hypertension commonly coexists with T2DM and can lead to cardiovascular complications. The analysis assesses blood pressure control indicators, including systolic and diastolic blood pressure measurements, antihypertensive medication adherence, and lifestyle modifications. It aims to determine the adequacy of blood pressure management in cancer survivors with T2DM [10].

Lipid profile

Dyslipidemia is prevalent in individuals with T2DM and poses an additional cardiovascular risk for cancer survivors. The analysis includes indicators such as lipid profiles (total cholesterol, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol, and triglycerides) and the use of lipid-lowering medications. The assessment provides insights into the management of dyslipidemia in cancer survivors with T2DM [11, 12].

Preventive care

Preventive care measures, such as annual foot examinations, eye examinations, and vaccinations, are crucial in preventing diabetes-related complications in cancer survivors. The analysis evaluates the adherence to these preventive care indicators and highlights areas where interventions can be implemented to improve the delivery of preventive services in this population [13 ].

Adherence to diabetes medications and screenings

Cancer survivors with T2DM may face unique challenges in medication adherence and adherence to regular diabetes screenings. The analysis examines indicators of medication adherence, such as medication possession ratios, as well as rates of regular diabetes screenings, such as retinopathy screenings and kidney function tests. It identifies potential barriers to adherence and strategies to improve medication adherence and screening rates [14, 15].

Conclusion

The comparative analysis of type 2 diabetes management quality indicators in cancer survivors provides valuable insights into the areas that require attention and improvement in diabetes care for this specific patient population. By assessing glycemic control, blood pressure management, lipid profile, preventive care, and medication adherence, healthcare providers can develop targeted interventions and personalized management strategies to optimize diabetes care in cancer survivors. This analysis serves as a foundation for further research and the development of comprehensive care models that address the unique needs of cancer survivors with T2DM, ultimately improving their long-term health outcomes and quality of life.

Acknowledgement

None

Conflict of Interest

None

References

  1. Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, et al. (2016) Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes 14: 18.

    2. Indexed at, Google Scholar, Crossref

  2. Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG (2018) Healthcare cost and utilization in non-alcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology (Baltimore, Md) 68: 2230-2238.

    3. Indexed at, Google Scholar, Crossref

  3. Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, et al. (2015) Non-alcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 110: 10-14.

    4. Indexed at, Google Scholar, Crossref

  4. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. (2019) Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med 17: 95.

    5. Indexed at, Google Scholar, Crossref

  5. Ezaz G, Trivedi HD, Connelly MA, Filozof C, Howard K, et al. (2020) Differential associations of circulating microRNAs with pathogenic factors in NAFLD. Hepatol Commun 4: 670-680.

    6. Indexed at, Google Scholar, Crossref

  6. Mäkimattila S, Harjutsalo V, Forsblom C, Groop PH (2020) FinnDiane Study Group. every fifth individual with type 1 diabetes suffers from an additional autoimmune disease: a Finnish nationwide study. Diabetes Care 43: 1041-1047.

    7. Indexed at, Google Scholar, Crossref

  7. Adamsson Eryd S, Svensson AM, Franzén S, Eliasson B, Nilsson PM, et al. (2017) Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med 34: 411-418.

    8. Indexed at, Google Scholar, Crossref

  8. Bjerg L, Hulman A, Carstensen B, Charles M, Witte DR, et al. (2019) Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study. Diabetologia 62: 633-643.

    9. Indexed at, Google Scholar, Crossref

  9. Głowinska-Olszewska B, Borysewicz-Sańczyk H, Sawicka B, Klonowska B, Charemska D, et al. (2020) Does Hashimoto's thyroiditis increase the risk of cardiovascular disease in young Type 1 diabetic patients? Front Endocrinol (Lausanne) 11: 431.

    10. Indexed at, Google Scholar, Crossref

  10. Ogarek N, Mrówka A, Jarosz-Chobot P (2021) Thyroid diseases - ally or enemy of type 1 diabetes in children and adolescents? Pediatr Endocrinol Diabetes Metab 27: 117-122.

    11. Indexed at, Google Scholar, Crossref

  11. Kilpatrick ES, Rigby AS, Atkin SL (2008) A1c variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31: 2198-2202.

    12. Indexed at, Google Scholar, Crossref

  12. Cavalot F (2013) Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab 15: 3-8.

    13. Indexed at, Google Scholar, Crossref

  13. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, et al. (2015) Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care 38: 2354-2369.

    14. Indexed at, Google Scholar, Crossref

  14. Sugawara A, Kawai K, Motohashi S (2012) HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia 55: 2128-2131.

    15. Indexed at, Google Scholar, Crossref

  15. Luk AO, Ma RC, Lau ES (2013) Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 29: 384-390.

    16. Indexed at, Google Scholar, Crossref

Author Info

Maltie Harewood*
 
Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, Barbados
 

Citation: Maltie Harewood. Type 2 Diabetes Management Quality Indicators in Cancer Survivors: A Comparative Analysis. J Diabetes Metab, 2023, 14(6): 1016.

Received: 30-May-2023, Manuscript No. jdm-23-25159; Editor assigned: 02-Jun-2023, Pre QC No. jdm-23-25159(PQ); Reviewed: 16-Jun-2023, QC No. jdm-23-25159; Revised: 23-Jun-2023, Manuscript No. jdm-23-25159(R); Published: 30-Jun-2023, DOI: 10.35248/2155-6156.10001016

Copyright: © 2023 Harewood M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

iomcworld scan

Journal Highlights

Journal Flyer

Flyer

+44 330-822-4832